Advantage Alpha Capital Partners LP Krystal Biotech, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 2,289 shares of KRYS stock, worth $364,614. This represents 0.1% of its overall portfolio holdings.
Number of Shares
2,289Holding current value
$364,614% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding KRYS
# of Institutions
310Shares Held
24.3MCall Options Held
483KPut Options Held
364K-
Black Rock Inc. New York, NY3.95MShares$629 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.85MShares$454 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.62MShares$418 Million7.18% of portfolio
-
State Street Corp Boston, MA1.45MShares$231 Million0.01% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA988KShares$157 Million9.67% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $4.09B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...